Skip to content

GlideSheath Slender® Versus Conventional 6 French Arterial Sheath: Impact on the Distal Radial Artery Occlusion (SMART)

GlideSheath Slender® Versus Conventional 6 French Arterial Sheath: Impact on the Incidence of Distal Radial Artery Occlusion in Cardiovascular Intervention Via Distal Radial Artery (SMART)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05501925
Acronym
SMART
Enrollment
600
Registered
2022-08-16
Start date
2022-09-15
Completion date
2024-02-28
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Coronary Artery Disease

Keywords

distal radial artery, distal radial artery occlusion, cardiovascular intervention

Brief summary

Compared with conventional artery sheath (TERUMO, Introducer II ), GlideSheath Slender® has more smaller outer-side diameter. The investigators suspected that use of the GlideSheath Slender® can reduce the incidence of distal radial artery occlusion in cardiovascular intervention via dTRA approach.

Detailed description

Distal transradial artery (dTRA) approach has emerged as a new approach in cardiovascular intervention in recent years. Compared to the conventional radial artery (CRA) approach, the dTRA approach dramatically reduced the risk of radial artery occlusion (RAO). In recent years, the incidence of distal radial artery occlusion (dRAO) after dTRA intervention has been reported in the literature, ranged from 0.12% to 5.2%. Outside diameter of artery sheath may affect the incidence of dRAO. Retrospective study reported that an artery/ sheath ratio \> 1.0 was least damaging to the vessel during coronary intervention via dTRA. Compared with conventional artery sheath (TERUMO, Introducer II ), 6 French GlideSheath Slender® has more smaller outer-side diameter (2.46mm vs. 2.62mm). The investigators suspected that use of the GlideSheath Slender can reduce the incidence of dRAO in cardiovascular intervention via dTRA approach.

Interventions

DEVICEGlideSheath Slender® and conventional arterial sheath

Using the GlideSheath Slender® with the outside diameter 2.46mm

DEVICEConventional arterial sheath

Placement of 6 French conventional Sheath (TERUMO, Introducer II )

Sponsors

Wujin People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Intervention model description

GlideSheath Slender® group Conventional Sheath group (TERUMO, Introducer II )

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Palpable distal radial and conventional radial artery

Exclusion criteria

* Age ≥ 90years * Height≥ 185cm * ST-segment elevation myocardial infarction or Cardiogenic shock * Contraindications to puncture at the puncture site * Diameter of DRA less than 1.5mm or RAO

Design outcomes

Primary

MeasureTime frameDescription
Rate of distal radial artery occlusion24 hours after the coronary angiography or interventionThe rate of distal radial artery occlusion is evaluated by ultrasound

Secondary

MeasureTime frameDescription
Rate of radial artery occlusion24 hours after the coronary angiography or interventionThe rate of radial artery occlusion is evaluated by ultrasound
Pain during the placement of the sheath24 hours after the coronary angiography or interventionVisual analog scale is used to evaluate the pain during the placement of the sheath, which ranges from 0-10, and 0 meas no pain
Radial artery dissection24 hours after the coronary angiography or interventionThe incidence of dissection of the radial artery is evaluated by ultrasound
Time of hemostasis24 hours after the coronary angiography or interventionThe time from the compress to hemostasis
Haematoma24 hours after the coronary angiography or interventionThe incidence of haematoma is evaluated by Early Discharge After Transradial Stenting of Coronary Arteries Study criteria

Countries

China

Contacts

Primary ContactGaojun Cai, Dr.
cgj982@126.com086-0519-85579193

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026